NO20074895L - Isoksazolin derivat og ny fremgangsmate for fremstilling derav - Google Patents

Isoksazolin derivat og ny fremgangsmate for fremstilling derav

Info

Publication number
NO20074895L
NO20074895L NO20074895A NO20074895A NO20074895L NO 20074895 L NO20074895 L NO 20074895L NO 20074895 A NO20074895 A NO 20074895A NO 20074895 A NO20074895 A NO 20074895A NO 20074895 L NO20074895 L NO 20074895L
Authority
NO
Norway
Prior art keywords
preparation
novel process
isoxazoline derivative
derivative
isoxazoline
Prior art date
Application number
NO20074895A
Other languages
English (en)
Other versions
NO341347B1 (no
Inventor
Hyun-Ik Shin
Ki-Sook Park
Hyeong-Wook Choi
Jae-Hoon Lee
Tae-Ho Heo
Kyo Woong Lee
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of NO20074895L publication Critical patent/NO20074895L/no
Publication of NO341347B1 publication Critical patent/NO341347B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Den foreliggende oppfinnelsen angår et isoksazolinderivat med den sykliske karboksylsyrehemiketalgruppen med formel (1), for anvendelse som en kaspasehemmer, en fremgangsmåte for dets fremstilling, foruten en farmasøytisk sammensetning som omfatter derivatet.
NO20074895A 2005-02-26 2007-09-26 Isoksazolin derivat og ny fremgangsmåte for fremstilling derav NO341347B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20050016203 2005-02-26
PCT/KR2006/000576 WO2006090997A1 (en) 2005-02-26 2006-02-21 Isoxazoline derivative and novel process for its preparation

Publications (2)

Publication Number Publication Date
NO20074895L true NO20074895L (no) 2007-11-26
NO341347B1 NO341347B1 (no) 2017-10-16

Family

ID=36927605

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074895A NO341347B1 (no) 2005-02-26 2007-09-26 Isoksazolin derivat og ny fremgangsmåte for fremstilling derav

Country Status (28)

Country Link
US (1) US8044080B2 (no)
EP (1) EP1851214B1 (no)
JP (1) JP4961357B2 (no)
KR (1) KR100774999B1 (no)
CN (1) CN101128459B (no)
AP (1) AP2374A (no)
AR (1) AR055314A1 (no)
AU (1) AU2006217293B2 (no)
BR (1) BRPI0607330B1 (no)
CA (1) CA2598347C (no)
DK (1) DK1851214T3 (no)
EA (1) EA013005B1 (no)
ES (1) ES2394480T3 (no)
IL (1) IL185226A0 (no)
MA (1) MA29311B1 (no)
MX (1) MX2007010338A (no)
MY (1) MY149181A (no)
NO (1) NO341347B1 (no)
NZ (1) NZ560805A (no)
PE (1) PE20061076A1 (no)
PL (1) PL1851214T3 (no)
PT (1) PT1851214E (no)
SG (1) SG156689A1 (no)
SI (1) SI1851214T1 (no)
TW (1) TWI377205B (no)
UA (1) UA94395C2 (no)
WO (1) WO2006090997A1 (no)
ZA (1) ZA200707202B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101299720B1 (ko) * 2006-08-16 2013-08-28 주식회사 엘지생명과학 3-아미노-5-플루오로-4-디알콕시펜탄산 에스테르의 새로운제조방법
KR20090099886A (ko) * 2008-03-18 2009-09-23 주식회사 엘지생명과학 캐스파제 저해제의 프로드럭
TW201012816A (en) * 2008-07-11 2010-04-01 Gilead Sciences Inc Method of treatment and pharmaceutical compositions
AR072181A1 (es) * 2008-07-11 2010-08-11 Gilead Sciences Inc Metodo de tratamiento y composiciones farmaceuticas que comprenden (r)-n-((2s,3s)-2-(fluorometil)-2-hidroxi-5-oxo-tetrahidrofuran-3-il)-5-isopropil-3-(isoquinolin-1-il)-4,5-dihidroisoxazol-5-carboxamida y uso
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
BR112015007159A2 (pt) * 2012-09-28 2017-07-04 Bayer Cropscience Ag compostos heterocíclicos que contêm azoto para o controle de doenças de plantas
JP2017095353A (ja) * 2014-03-27 2017-06-01 日本曹達株式会社 イソオキサゾリン−５−カルボキサミド化合物および有害生物防除剤
CN113354708B (zh) * 2017-01-23 2024-05-14 正大天晴药业集团股份有限公司 作为Caspase抑制剂的联环化合物
KR102437095B1 (ko) * 2019-04-19 2022-08-26 주식회사 엘지화학 캐스파제 저해제의 프로드럭
CN113767097B (zh) * 2019-04-30 2025-03-14 株式会社Lg化学 半胱天冬酶抑制剂的前药
US12257341B2 (en) 2019-05-31 2025-03-25 Lg Chem, Ltd. Injectable composition containing prodrug of caspase inhibitors, and preparation method therefor
US20220226306A1 (en) * 2019-05-31 2022-07-21 Lg Chem, Ltd. Composition for caspase inhibitor prodrug injection
CN116113413A (zh) * 2020-08-05 2023-05-12 株式会社Lg化学 胱天蛋白酶抑制剂用于缓解或治疗骨关节炎的用途
KR20220076371A (ko) 2020-11-30 2022-06-08 주식회사 엘지화학 캐스파제 저해제를 함유하는 주사용 조성물 및 이의 제조 방법
KR102670554B1 (ko) * 2022-01-04 2024-05-30 주식회사 이노보테라퓨틱스 캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물
AU2023208459A1 (en) * 2022-01-24 2024-07-11 Lg Chem, Ltd. Injectable formulation containing isoxazoline derivative
EP4467126A4 (en) 2022-02-23 2025-04-30 LG Chem, Ltd. Injectable formulation containing isoxazoline derivative and method for producing the same
EP4467127A4 (en) 2022-03-24 2025-05-21 LG Chem, Ltd. Injectable preparation comprising isoxazoline derivative, and preparation method therefor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021599A1 (en) * 1999-09-17 2001-03-29 Lg Chemical Ltd. Caspase inhibitor
WO2001021600A1 (en) * 1999-09-17 2001-03-29 Lg Chem Investment Ltd. Caspase inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100373375B1 (ko) * 1998-04-03 2003-06-12 주식회사 엘지생명과학 인터루킨-1b-컨버팅효소및아포파인/cpp-32에대한저해제
KR19990079267A (ko) * 1998-04-03 1999-11-05 성재갑 이소옥사졸(또는 이소옥사졸린) 구조를 갖는 파네실 전이효소억제제
KR100594544B1 (ko) * 2003-08-27 2006-06-30 주식회사 엘지생명과학 이소옥사졸린 구조를 갖는 캐스파제 저해제
TWI256952B (en) * 2003-08-27 2006-06-21 Sk Corp Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021599A1 (en) * 1999-09-17 2001-03-29 Lg Chemical Ltd. Caspase inhibitor
WO2001021600A1 (en) * 1999-09-17 2001-03-29 Lg Chem Investment Ltd. Caspase inhibitor

Also Published As

Publication number Publication date
CA2598347C (en) 2011-08-02
TW200640918A (en) 2006-12-01
NZ560805A (en) 2010-12-24
EA013005B1 (ru) 2010-02-26
HK1111146A1 (en) 2008-08-01
ES2394480T3 (es) 2013-02-01
KR20060094868A (ko) 2006-08-30
EP1851214B1 (en) 2012-09-05
ZA200707202B (en) 2008-10-29
US8044080B2 (en) 2011-10-25
TWI377205B (en) 2012-11-21
US20080262032A1 (en) 2008-10-23
CA2598347A1 (en) 2006-08-31
BRPI0607330A2 (pt) 2009-09-29
BRPI0607330B1 (pt) 2021-08-03
SI1851214T1 (sl) 2012-11-30
CN101128459A (zh) 2008-02-20
AU2006217293B2 (en) 2012-02-02
DK1851214T3 (da) 2012-10-15
EP1851214A4 (en) 2009-10-28
MY149181A (en) 2013-07-31
IL185226A0 (en) 2008-02-09
SG156689A1 (en) 2009-11-26
AR055314A1 (es) 2007-08-15
AP2374A (en) 2012-03-07
PE20061076A1 (es) 2006-12-27
MX2007010338A (es) 2007-10-11
CN101128459B (zh) 2011-10-05
UA94395C2 (ru) 2011-05-10
AU2006217293A1 (en) 2006-08-31
KR100774999B1 (ko) 2007-11-09
WO2006090997A1 (en) 2006-08-31
EA200701810A1 (ru) 2008-02-28
JP2008531551A (ja) 2008-08-14
MA29311B1 (fr) 2008-03-03
JP4961357B2 (ja) 2012-06-27
EP1851214A1 (en) 2007-11-07
PT1851214E (pt) 2012-10-18
PL1851214T3 (pl) 2013-03-29
NO341347B1 (no) 2017-10-16

Similar Documents

Publication Publication Date Title
MX367154B (es) Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benz oico.
NO20085068L (no) Fenylamino-benzoksazolsubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
SE0301010D0 (sv) Novel compounds
SE0301009D0 (sv) Novel compounds
NO20050741L (no) Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
EA201070699A1 (ru) Композиции 3-(6-(1-2,2-дифторбензо[d][1,3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20090328L (no) Nye forbindelser 385
NO20091626L (no) MGLUR5-modulatorer
NO20090327L (no) Nye forbindelser 384
NO20082496L (no) Pyrazinderivater
TW200640918A (en) Isoxazoline derivative and novel process for its preparation
NO20076059L (no) 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer
ATE491446T1 (de) Ligustilid zur behandlung von erkrankungen des zentralen nervensystems
NO20063821L (no) Kinolinderivater for anvendelse som mykobakterielle inhibitorer
NO20085212L (no) Nye pyridinanaloger
NO20076448L (no) Novel piperidine carboxylic acid amide derivatives
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
NO20080394L (no) N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav
NO20064078L (no) Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter
NO20064351L (no) Caspaseinhibitorer og anvendelser derav
BRPI0411087A (pt) aperfeiçoamentos em ou relacionados a compostos orgánicos

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: LG CHEM, KR